PFE Net income
Net income at Pfizer fell to $7.8B in fiscal 2025, from $8.0B in 2024.
Net income attributable to the parent / common stockholders, as filed.
SOURCE: us-gaap:NetIncomeLoss · EDGAR CompanyFacts · CIK 78003 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Net income | Change |
|---|---|---|
| FY2025 | $7.8B | $-260M |
| FY2024 | $8.0B | +$5.9B |
| FY2023 | $2.1B | $-29.3B |
| FY2022 | $31.4B | +$9.4B |
| FY2021 | $22.0B | — |
Cross-checks touching this measure FROM THE FILING REVIEW
✗ RED FLAGCash conversion stability
The ratio of operating cash flow to net income swings 2.53× across three years. This page verifies no stated cause; the flag marks the size of the swing. Management's own account touching these lines appears in the "operating cash flow" claim on this page (confirmed); this page has not independently verified it.
FY2025 10-K · FULL RECONCILIATION →More SAME DATA, OTHER VIEWS
Net income across coverage → · PFE company view →
Revenue · Operating cash flow · Free cash flow · Capital expenditure · Cash & equivalents · Total assets · Shareholders' equity · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.